Records 101–140 of 290. Open a study to inspect the full evidence record. Source links lead directly to the publication. Updated 19 October 2026.
Immunity and respiratory health (1) · Forms, absorption and food sources (3) · Skin and topical formulations (1) · Cardiovascular and metabolic health (10) · Brain, cognition and sleep (1) · Hormones and reproductive health (4) · Safety, interactions and special populations (6) · Exercise and recovery (7) · Prostate and urinary health (1) · Bone and joint health (1) · Senescence and longevity (1) · Evidence reviews and human mechanisms (1) · Inflammation and clinical symptoms (2) · Allergies, histamine and mast cells (1)
Meta-analysis of randomized controlled human trials. Overall CRP, IL-6, and TNF-alpha did not improve; selected subgroups showed reductions.
Randomized controlled acute crossover study. Flow-mediated dilation and circulating metabolites increased. Blood pressure, arterial stiffness and cognition did not change.
Human intestinal sampling and comparative laboratory metabolism study. Human intestinal metabolite profiles differed from HT29 cell profiles; 3D tissues reproduced more of the human pattern.
Randomized fasting crossover pharmacokinetic trial. The lecithin formulation increased measured quercetin exposure and peak concentration compared with unformulated quercetin.
Randomized active-comparator topical pilot trial. The nanohydrogel group had shorter wound-healing time than the comparator.
Systematic review and meta-analysis of randomized trials. Pooled systolic and diastolic pressure decreased; overall lipid and glucose outcomes were not significantly changed.
Randomized double-blind placebo-controlled pilot trial. Red-cell indices and ferritin differed from placebo, with changes in both directions across blood measures.
Randomized double-blind placebo-controlled phase 2 pilot. The primary flow-mediated dilation endpoint and other vascular, inflammatory and kidney outcomes did not improve significantly.
Randomized double-blind placebo-controlled crossover trial. Lipids improved similarly in both conditions, without an added quercetin effect on blood pressure, inflammation or oxidative measures.
Systematic review and meta-analysis of randomized trials. Overall fasting glucose, insulin resistance, and HbA1c did not improve; selected dose or duration subgroups showed favorable findings.
Systematic review and meta-analysis of randomized trials. Systolic pressure decreased modestly; diastolic pressure and measured adhesion molecules did not significantly change.
Systematic review and meta-analysis of randomized trials. Overall LDL, HDL, triglycerides, and total cholesterol did not differ significantly; selected higher-dose subgroups favored LDL reduction.
Narrative review of human dietary bioavailability and vascular evidence. Chemical form and food matrix affect absorption, and selected trials suggest vascular biomarker effects.
Randomized double-blind placebo-controlled adjunctive trial. ALT decreased compared with placebo. Most antioxidant and liver-enzyme endpoints did not differ significantly.
Randomized double-blind placebo-controlled food trial. The primary visceral-fat comparison was null. A lower-HDL subgroup and an ALT measure showed favorable signals.
Systematic review of animal Alzheimer-model studies. The review reports favorable behavioral and biological findings in experimental Alzheimer models.
Systematic review of mixed human and animal PCOS evidence. The review describes favorable hormonal, metabolic, and ovarian findings in parts of the literature, without consistent weight effects.
Uncontrolled clinical endometriosis study with supporting laboratory work. Pain symptoms and reported NSAID use decreased from baseline.
Randomized double-blind placebo-controlled PCOS trial. Adiponectin-receptor transcripts and an AMPK measure increased relative to placebo.
Randomized double-blind placebo-controlled PCOS trial. Resistin, testosterone and LH measures decreased relative to placebo. Glucose, insulin and HOMA-IR changes were not significant between groups.
Randomized placebo-controlled dose-escalation safety trial. No drug-related severe adverse events were reported over the short dosing period.
Uncontrolled short-term medication non-interference study. The measured bleeding-time, INR and glycemic endpoints did not change significantly from baseline.
Open-label phase 2 sequential dose-cohort study. Coagulation biomarkers, including D-dimer at the higher dose, declined. No primary venous-thrombosis events or major hemorrhages were observed.
Open-label two-period sequential drug-interaction study. Chlorzoxazone exposure and peak concentration increased, while metabolite formation decreased.
Open-label two-period sequential drug-interaction study. Diclofenac exposure increased while its hydroxylated metabolite decreased, supporting an interaction under the tested conditions.
Narrative mechanistic review of iron metabolism. The review discusses iron binding, redox effects, and regulation of iron handling beyond simple chelation.
Randomized double-blind exercise trial. The combination reduced reported pain and loss of jumping performance; race times did not improve.
Double-blind crossover exercise study. Quercetin attenuated post-exercise strength loss and several muscle-damage measures.
Randomized double-blind crossover exercise trial. Quercetin attenuated immediate weakness and neuromuscular impairment after the damaging exercise protocol.
Randomized double-blind placebo-controlled protein-supplement trial. Lower-limb fat-free and muscle-mass changes favored the EMIQ protein group. Overall body and lean-mass outcomes did not differ.
Randomized double-blind acute crossover exercise study. Some strength, torque-development and exercise-volume measures favored quercetin. Blood damage markers did not differ.
Randomized controlled crossover exercise study. Red-cell lipid-peroxidation and hemolysis-susceptibility measures improved, while resting antioxidant-enzyme and glutathione measures did not.
Published observational athlete supplement registry. Training-run time and self-reported recovery measures improved more in supplemented participants.
Randomized parallel placebo-controlled presurgical study. Quercetin exposure increased, but prostate green-tea-polyphenol content and methylation activity did not differ significantly.
Narrative review of predominantly preclinical bone research. Most reviewed models suggested bone-protective effects, although some results were negative or pathway-dependent.
Open-label two-center feasibility pilot. Walking and chair-stand measures improved from baseline, while lung function and reported health did not. Adverse events included one serious event.
Systematic review and meta-analysis of randomized trials. Pooled analyses did not show significant reductions in body weight, BMI, waist circumference or waist-to-hip ratio.
Randomized double-blind placebo-controlled trial. Iron, ferritin, transferrin saturation and hs-CRP fell versus placebo; TNF-alpha and total iron-binding capacity did not differ.
Randomized double-blind active-comparator flavonoid trial. Bleeding improved similarly in both groups. Satisfaction favored the quercetin-containing mixture at 6 months.
Published observational supplement registry with clinical outcomes. The authors report favorable symptom, rescue-medication, and peak-flow findings in supplemented participants.
Design tiers organize different kinds of evidence; read the source-specific limitations before applying a result. The full library is curated by Biohack Blueprint. Each evidence record lists its editorial author and reviewers.
